About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 984241, 13 pages
http://dx.doi.org/10.1155/2011/984241
Review Article

Protective Role of Cytotoxic T Lymphocytes in Filovirus Hemorrhagic Fever

1Vaccine Development, Integrated Biotherapeutics, Inc., 21 Firstfield Road Suite 100, Gaithersburg, MD 20878, USA
2Virology Division, The United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA

Received 29 June 2011; Accepted 21 October 2011

Academic Editor: Hanchun Yang

Copyright © 2011 Kelly Lyn Warfield and Gene Garrard Olinger. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. S. Towner, T. K. Sealy, M. L. Khristova et al., “Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda,” PLoS Pathogens, vol. 4, no. 11, Article ID e1000212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Sanchez, M. P. Kiley, B. P. Holloway, and D. D. Auperin, “Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus,” Virus Research, vol. 29, no. 3, pp. 215–240, 1993. View at Publisher · View at Google Scholar · View at Scopus
  3. C. F. Basler, X. Wang, E. Mühlberger et al., “The Ebola virus VP35 protein functions as a type I IFN antagonist,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 12289–12294, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Mühlberger, M. Weik, V. E. Volchkov, H. D. Klenk, and S. Becker, “Comparison of the transcription and replication strategies of Marburg virus and ebola virus by using artificial replication systems,” Journal of Virology, vol. 73, no. 3, pp. 2333–2342, 1999. View at Scopus
  5. J. Burke, R. Declerq, and G. Ghysebrechts, “Ebola haemorrhagic fever in Zaire, 1976. Report of an international commission,” Bulletin of the World Health Organization, vol. 56, no. 2, pp. 271–293, 1978. View at Scopus
  6. I. M. Deng, O. Duku, and A. L. Gillo, “Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team,” Bulletin of the World Health Organization, vol. 56, no. 2, pp. 247–270, 1978. View at Scopus
  7. B. M. Connolly, K. E. Steele, K. J. Davis et al., “Pathogenesis of experimental Ebola virus infection in guinea pigs,” Journal of Infectious Diseases, vol. 179, supplement 1, pp. S203–S217, 1999. View at Scopus
  8. E. I. Ryabchikova, L. V. Kolesnikova, and S. V. Netesov, “Animal pathology of filoviral infections,” Current Topics in Microbiology and Immunology, vol. 235, pp. 145–173, 1999.
  9. U. Ströher, E. West, H. Bugany, H. D. Klenk, H. J. Schnittler, and H. Feldmann, “Infection and activation of monocytes by Marburg and Ebola viruses,” Journal of Virology, vol. 75, no. 22, pp. 11025–11033, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. E. M. Leroy, B. Kumulungui, X. Pourrut et al., “Fruit bats as reservoirs of Ebola virus,” Nature, vol. 438, no. 7068, pp. 575–576, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. J. S. Towner, X. Pourrut, C. G. Albariño et al., “Marburg virus infection detected in a common African bat,” PLoS ONE, vol. 2, no. 8, article e764, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. E. F. Belanov, V. P. Muntianov, V. D. Kriuk et al., “Survival of Marburg virus infectivity on contaminated surfaces and in aerosols,” Voprosy Virusologii, vol. 41, no. 1, pp. 32–34, 1996. View at Scopus
  13. V. G. Frolov and I. M. Gusev, “Stability of Marburg virus to lyophilization process and subsequent storage at different temperatures,” Voprosy Virusologii, vol. 41, no. 6, pp. 275–277, 1996. View at Scopus
  14. E. Johnson, N. Jaax, J. White, and P. Jahrling, “Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus,” International Journal of Experimental Pathology, vol. 76, no. 4, pp. 227–236, 1995. View at Scopus
  15. E. Ryabchikova, L. Strelets, L. Kolesnikova, O. Pyankov, and A. Sergeev, “Respiratory Marburg virus infection in guinea pigs,” Archives of Virology, vol. 141, no. 11, pp. 2177–2190, 1996. View at Scopus
  16. N. K. Jaax, K. J. Davis, T. J. Geisbert et al., “Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure,” Archives of Pathology and Laboratory Medicine, vol. 120, no. 2, pp. 140–155, 1996. View at Scopus
  17. M. Mohamadzadeh, L. Chen, and A. L. Schmaljohn, “How Ebola and Marburg viruses battle the immune system,” Nature Reviews Immunology, vol. 7, no. 7, pp. 556–567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. D. S. Reed and M. Mohamadzadeh, “Status and challenges of filovirus vaccines,” Vaccine, vol. 25, no. 11, pp. 1923–1934, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Hevey, D. Negley, L. VanderZanden et al., “Marburg virus vaccines: comparing classical and new approaches,” Vaccine, vol. 20, no. 3-4, pp. 586–593, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. G. M. Ignat'ev, M. A. Strel'tsova, A. P. Agafonov, N. A. Zhukova, E. A. Kashentseva, and M. S. Vorob'eva, “The immunity indices of animals immunized with the inactivated Marburg virus after infection with homologous virus,” Voprosy Virusologii, vol. 39, no. 1, pp. 13–17, 1994. View at Scopus
  21. G. M. Ignatev, A. P. Agafonov, M. A. Strel'tsova, et al., “A comparative study of the immunological indices in guinea pigs administered an inactivated Marburg virus,” Voprosy Virusologii, vol. 36, pp. 421–423, 1991.
  22. G. M. Ignatyev, A. P. Agafonov, M. A. Streltsova, and E. A. Kashentseva, “Inactivated marburg virus elicits a nonprotective immune response in Rhesus monkeys,” Journal of Biotechnology, vol. 44, no. 1–3, pp. 111–118, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. T. W. Geisbert, P. Pushko, K. Anderson, J. Smith, K. J. Davis, and P. B. Jahrling, “Evaluation in nonhuman primates of vaccines against Ebola virus,” Emerging Infectious Diseases, vol. 8, no. 5, pp. 503–507, 2002. View at Scopus
  24. H. W. Lupton, R. D. Lambert, and D. L. Bumgardner, “Inactivated vaccine for Ebola virus efficacious in guinea pig model,” The Lancet, vol. 2, no. 8207, pp. 1294–1295, 1980. View at Scopus
  25. M. Rao, M. Bray, C. R. Alving, P. Jahrling, and G. R. Matyas, “Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated ebola virus: protection in mice requires CD4+ T cells,” Journal of Virology, vol. 76, no. 18, pp. 9176–9185, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. T. W. Geisbert and P. B. Jahrling, “Towards a vaccine against Ebola virus,” Expert Review of Vaccines, vol. 2, no. 6, pp. 777–789, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. V. V. Mikhailov, I. V. Borisevich, N. K. Chernikova, N. V. Potryvaeva, and V. P. Krasnianskii, “The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever,” Voprosy Virusologii, vol. 39, no. 2, pp. 82–84, 1994.
  28. M. Hevey, D. Negley, J. Geisbert, P. Jahrling, and A. Schmaljohn, “Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants,” Virology, vol. 239, no. 1, pp. 206–216, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Riemenschneider, A. Garrison, J. Geisbert et al., “Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus,” Vaccine, vol. 21, no. 25-26, pp. 4071–4080, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. T. W. Geisbert, M. Bailey, J. B. Geisbert et al., “Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates,” Journal of Virology, vol. 84, no. 19, pp. 10386–10394, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. J. L. Mellquist-Riemenschneider, A. R. Garrison, J. B. Geisbert et al., “Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for Ebola virus in guinea pigs,” Virus Research, vol. 92, no. 2, pp. 187–193, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Konduru, S. B. Bradfute, J. Jacques et al., “Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice,” Vaccine, vol. 29, no. 16, pp. 2968–2977, 2011. View at Publisher · View at Google Scholar
  33. M. K. Hart, “Vaccine research efforts for filoviruses,” International Journal for Parasitology, vol. 33, no. 5-6, pp. 583–595, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Garbutt, R. Liebscher, V. Wahl-Jensen et al., “Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses,” Journal of Virology, vol. 78, no. 10, pp. 5458–5465, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Pushko, J. Geisbert, M. Parker, P. Jahrling, and J. Smith, “Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses,” Journal of Virology, vol. 75, no. 23, pp. 11677–11685, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Pushko, M. Bray, G. V. Ludwig et al., “Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus,” Vaccine, vol. 19, no. 1, pp. 142–153, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. J. A. Wilson and M. K. Hart, “Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein,” Journal of Virology, vol. 75, no. 6, pp. 2660–2664, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Hevey, D. Negley, P. Pushko, J. Smith, and A. Schmaljohn, “Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates,” Virology, vol. 251, no. 1, pp. 28–37, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. N. J. Sullivan, A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel, “Development of a preventive vaccine for Ebola virus infection in primates,” Nature, vol. 408, no. 6812, pp. 605–609, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. G. J. Nabel, “Vaccine for AIDS and Ebola virus infection,” Virus Research, vol. 92, no. 2, pp. 213–217, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. N. J. Sullivan, T. W. Geisbert, J. B. Gelsbert et al., “Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates,” Nature, vol. 424, no. 6949, pp. 681–684, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Bukreyev, P. E. Rollin, M. K. Tate et al., “Successful topical respiratory tract immunization of primates against Ebola virus,” Journal of Virology, vol. 81, no. 12, pp. 6379–6388, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Bukreyev, L. Yang, S. R. Zaki et al., “A single intranasal inoculation with a paramyxoviras-vectored vaccine protects guinea pigs against a lethal-dose ebola virus challenge,” Journal of Virology, vol. 80, no. 5, pp. 2267–2279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Falzarano, T. W. Geisbert, and H. Feldmann, “Progress in filovirus vaccine development: evaluating the potential for clinical use,” Expert Review of Vaccines, vol. 10, no. 1, pp. 63–77, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. D. G. Bausch, A. G. Sprecher, B. Jeffs, and P. Boumandouki, “Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions,” Antiviral Research, vol. 78, no. 1, pp. 150–161, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. T. W. Geisbert, L. E. Hensley, P. B. Jahrling et al., “Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys,” The Lancet, vol. 362, no. 9400, pp. 1953–1958, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. L. E. Hensley, E. L. Stevens, S. B. Yan et al., “Recombinant human activated protein C for the postexposure treatment of ebola hemorrhagic fever,” Journal of Infectious Diseases, vol. 196, no. 2, pp. S390–S399, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. K. M. Daddario-DiCaprio, T. W. Geisbert, U. Ströher et al., “Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment,” The Lancet, vol. 367, no. 9520, pp. 1399–1404, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. S. M. Jones, U. Ströher, L. Fernando et al., “Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever,” Journal of Infectious Diseases, vol. 196, supplement 2, pp. S404–S412, 2007. View at Publisher · View at Google Scholar
  50. H. Feldmann, S. M. Jones, K. M. Daddario-DiCaprio et al., “Effective post-exposure treatment of Ebola infection,” PLoS Pathogens, vol. 3, no. 1, p. e2, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. K. L. Warfield, D. L. Swenson, G. G. Olinger et al., “Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers,” PLoS Pathogens, vol. 2, no. 1, p. e1, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. T. K. Warren, K. L. Warfield, J. Wells et al., “Advanced antisense therapies for postexposure protection against lethal filovirus infections,” Nature Medicine, vol. 16, no. 9, pp. 991–994, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. T. W. Geisbert, L. E. Hensley, E. Kagan et al., “Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference,” Journal of Infectious Diseases, vol. 193, no. 12, pp. 1650–1657, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. T. W. Geisbert, A. C. Lee, M. Robbins et al., “Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study,” The Lancet, vol. 375, no. 9729, pp. 1896–1905, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Baize, E. M. Leroy, M. C. Georges-Courbot et al., “Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients,” Nature Medicine, vol. 5, no. 4, pp. 423–426, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. J. Liu, “Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity,” Cell, vol. 106, no. 3, pp. 259–262, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. R. M. Steinman, “Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation,” Mount Sinai Journal of Medicine, vol. 68, no. 3, pp. 160–166, 2001. View at Scopus
  58. E. M. Leroy, S. Baize, P. Debre, J. Lansoud-Soukate, and E. Mavoungou, “Early immune responses accompanying human asymptomatic Ebola infections,” Clinical and Experimental Immunology, vol. 124, no. 3, pp. 453–460, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. E. M. Leroy, S. Baize, V. E. Volchkov et al., “Human asymptomatic Ebola infection and strong inflammatory response,” The Lancet, vol. 355, no. 9222, pp. 2210–2215, 2000. View at Scopus
  60. S. Baize, E. M. Leroy, A. J. Georges et al., “Inflammatory responses in Ebola virus-infected patients,” Clinical and Experimental Immunology, vol. 128, no. 1, pp. 163–168, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. K. L. Hutchinson and P. E. Rollin, “Cytokine and chemokine expression in humans infected with Sudan Ebola virus,” Journal of Infectious Diseases, vol. 196, no. 2, pp. S357–S363, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Villinger, P. E. Rollin, S. S. Brar et al., “Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection,” Journal of Infectious Diseases, vol. 179, no. 1, pp. S188–S191, 1999. View at Scopus
  63. N. Wauquier, P. Becquart, C. Padilla, S. Baize, and E. M. Leroy, “Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis,” PLoS Neglected Tropical Diseases, vol. 4, no. 10, article e837, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Gupta, S. Mahanty, R. Ahmed, and P. E. Rollin, “Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with Ebola virus secrete MIP-1α and TNF-α and inhibit poly-IC-induced IFN-α in vitro,” Virology, vol. 284, no. 1, pp. 20–25, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. C. F. Basler and G. K. Amarasinghe, “Evasion of interferon responses by ebola and marburg viruses,” Journal of Interferon and Cytokine Research, vol. 29, no. 9, pp. 511–520, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. C. M. Bosio, M. J. Aman, C. Grogan et al., “Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation,” Journal of Infectious Diseases, vol. 188, no. 11, pp. 1630–1638, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Mahanty, K. Hutchinson, S. Agarwal, M. Mcrae, P. E. Rollin, and B. Pulendran, “Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses,” Journal of Immunology, vol. 170, no. 6, pp. 2797–2801, 2003. View at Scopus
  68. T. W. Geisbert, L. E. Hensley, T. Larsen et al., “Pathogenesis of ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection,” American Journal of Pathology, vol. 163, no. 6, pp. 2347–2370, 2003. View at Scopus
  69. L. E. Hensley, H. A. Young, P. B. Jahrling, and T. W. Geisbert, “Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily,” Immunology Letters, vol. 80, no. 3, pp. 169–179, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. T. R. Gibb, D. A. Norwood Jr., N. Woollen, and E. A. Henchal, “Viral replication and host gene expression in alveolar macrophages infected with Ebola virus (Zaire strain),” Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 1, pp. 19–27, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. D. S. Reed, L. E. Hensley, J. B. Geisbert, P. B. Jahrling, and T. W. Geisbert, “Depletion of peripheral blood T lymphocytes and NK cells during the course of Ebola hemorrhagic fever in cynomolgus macaques,” Viral Immunology, vol. 17, no. 3, pp. 390–400, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. K. L. Warfield, J. G. Perkins, D. L. Swenson et al., “Role of natural killer cells innate protection against lethal Ebola virus infection,” Journal of Experimental Medicine, vol. 200, no. 2, pp. 169–179, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. T. W. Geisbert, K. M. Daddario-DiCaprio, K. J. N. Williams et al., “Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates,” Journal of Virology, vol. 82, no. 11, pp. 5664–5668, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. S. P. Fisher-Hoch, G. S. Platt, and G. H. Neild, “Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola),” Journal of Infectious Diseases, vol. 152, no. 5, pp. 887–894, 1985. View at Scopus
  75. S. Kim, K. Iizuka, H. L. Aguila, I. L. Weissman, and W. M. Yokoyama, “In vivo natural killer cell activities revealed by natural killer cell-deficient mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 6, pp. 2731–2736, 2000. View at Scopus
  76. N. Wauquier, C. Padilla, P. Becquart, E. Leroy, and V. Vieillard, “Association of KIR2DS1 and KIR2DS3 with fatal outcome in Ebola virus infection,” Immunogenetics, vol. 62, no. 11-12, pp. 767–771, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Gupta, C. Spiropoulou, and P. E. Rollin, “Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro,” Virology, vol. 364, no. 1, pp. 45–54, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. L. E. Hensley, H. A. Young, P. B. Jahrling, and T. W. Geisbert, “Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily,” Immunology Letters, vol. 80, no. 3, pp. 169–179, 2002. View at Publisher · View at Google Scholar · View at Scopus
  79. T. G. Ksiazek, P. E. Rollin, A. J. Williams et al., “Clinical virology of Ebola hemorrhagic fever (EHF): Virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995,” Journal of Infectious Diseases, vol. 179, no. 1, pp. S177–S187, 1999. View at Scopus
  80. M. Bray, K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins, “A mouse model for evaluation of prophylaxis and therapy of ebola hemorrhagic fever,” Journal of Infectious Diseases, vol. 178, no. 3, pp. 651–661, 1998. View at Scopus
  81. S. B. Bradfute, D. R. Braun, J. D. Shamblin et al., “Lymphocyte death in a mouse model of ebola virus infection,” Journal of Infectious Diseases, vol. 196, no. 2, pp. S296–S304, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. S. B. Bradfute, K. L. Warfield, and S. Bavari, “Functional CD8+ T cell responses in lethal ebola virus infection,” Journal of Immunology, vol. 180, no. 6, pp. 4058–4066, 2008. View at Scopus
  83. S. B. Bradfute, P. E. Swanson, M. A. Smith et al., “Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis,” Journal of Immunology, vol. 184, no. 1, pp. 327–335, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Gupta, S. Mahanty, P. Greer et al., “Persistent infection with Ebola virus under conditions of partial immunity,” Journal of Virology, vol. 78, no. 2, pp. 958–967, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. N. J. Sullivan, J. E. Martin, B. S. Graham, and G. J. Nabel, “Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule,” Nature Reviews Microbiology, vol. 7, no. 5, pp. 393–400, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. K. L. Warfield, G. Olinger, E. M. Deal et al., “Induction of humoral and CD8+ T cell responses are required for protection against lethal ebola virus infection,” Journal of Immunology, vol. 175, no. 2, pp. 1184–1191, 2005. View at Scopus
  87. J. A. Wilson, M. Hevey, R. Bakken et al., “Epitopes involved in antibody-mediated protection from Ebola virus,” Science, vol. 287, no. 5458, pp. 1664–1666, 2000. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Hevey, D. Negley, and A. Schmaljohn, “Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes,” Virology, vol. 314, no. 1, pp. 350–357, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. P. W. H. I. Parren, T. W. Geisbert, T. Maruyama, P. B. Jahrling, and D. R. Burton, “Pre-and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody,” Journal of Virology, vol. 76, no. 12, pp. 6408–6412, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Takada, H. Ebihara, S. Jones, H. Feldmann, and Y. Kawaoka, “Protective efficacy of neutralizing antibodies against Ebola virus infection,” Vaccine, vol. 25, no. 6, pp. 993–999, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. N. J. Sullivan, L. Hensley, C. Asiedu et al., “CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates,” Nature Medicine, vol. 17, no. 9, pp. 1128–1131, 2011. View at Publisher · View at Google Scholar
  92. W. B. Oswald, T. W. Geisbert, K. J. Davis et al., “Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys,” PLoS Pathogens, vol. 3, no. 1, p. e9, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. P. B. Jahrling, J. B. Geisbert, J. R. Swearengen, T. Larsen, and T. W. Geisbert, “Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates,” Journal of Infectious Diseases, vol. 196, supplement 2, pp. S400–S403, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. J. A. Wilson, M. Bray, R. Bakken, and M. K. Hart, “Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins,” Virology, vol. 286, no. 2, pp. 384–390, 2001. View at Publisher · View at Google Scholar · View at Scopus
  95. D. L. Swenson, K. L. Warfield, D. L. Negley, A. Schmaljohn, M. J. Aman, and S. Bavari, “Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections,” Vaccine, vol. 23, no. 23, pp. 3033–3042, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. G. G. Olinger, M. A. Bailey, J. M. Dye et al., “Protective cytotoxic T-cell responses induced by Venezuelan equine encephalitis virus replicons expressing Ebola virus proteins,” Journal of Virology, vol. 79, no. 22, pp. 14189–14196, 2005. View at Publisher · View at Google Scholar · View at Scopus
  97. J. H. Kuhn, Filoviruses: A Compendium of 40 Years of Epidemiological, Clinical, and Laboratory Studies, Springer, New York, NY, USA, 2008.
  98. W. Dowling, E. Thompson, C. Badger et al., “Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines,” Journal of Virology, vol. 81, no. 4, pp. 1821–1837, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Rao, G. R. Matyas, F. Grieder, K. Anderson, P. B. Jahrling, and C. R. Alving, “Cytotoxic T lymphocytes to Ebola Zaire virus are induced in mice by immunization with liposomes containing lipid A,” Vaccine, vol. 17, no. 23-24, pp. 2991–2998, 1999. View at Publisher · View at Google Scholar · View at Scopus
  100. G. Simmons, A. Lee, A. J. Rennekamp, X. Fan, P. Bates, and H. Shen, “Identification of murine T-cell epitopes in Ebola virus nucleoprotein,” Virology, vol. 318, no. 1, pp. 224–230, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. K. Sundar, A. Boesen, and R. Coico, “Computational prediction and identification of HLA-A2.1-specific Ebola virus CTL epitopes,” Virology, vol. 360, no. 2, pp. 257–263, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. W. V. Kalina, K. L. Warfield, G. G. Olinger, and S. Bavari, “Discovery of common marburgvirus protective epitopes in a BALB/c mouse model,” Virology Journal, vol. 6, article 132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. J. E. Martin, N. J. Sullivan, M. E. Enama et al., “A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial,” Clinical and Vaccine Immunology, vol. 13, no. 11, pp. 1267–1277, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. J. E. Ledgerwood, P. Costner, N. Desai et al., “A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults,” Vaccine, vol. 29, no. 2, pp. 304–313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. T. Vogel, S. Norley, B. Beer, and R. Kurth, “Rapid screening for Mamu-A1-positive rhesus macaques using a SIVmac gag peptide-specific cytotoxic T-lymphocyte assay,” Immunology, vol. 84, no. 3, pp. 482–487, 1995. View at Scopus
  106. D. G. Smith, S. Kanthaswamy, J. Viray, and L. Cody, “Additional highly polymorphic microsatellite (STR) loci for estimating kinship in rhesus macaques (Macaca mulatta),” American Journal of Primatology, vol. 50, no. 1, pp. 1–7, 2000. View at Scopus
  107. M. C. T. Penedo, R. E. Bontrop, C. M. C. Heijmans et al., “Microsatellite typing of the rhesus macaque MHC region,” Immunogenetics, vol. 57, no. 3-4, pp. 198–209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. J. R. Napier and P. H. Napier, A Handbook of Living Primates: Morphology, Ecology and Behavior of Nonhuman Primates, Academic Press, New York, NY, USA, 1967.
  109. “Guidance for industry, animal models—essential elements to address efficacy under the animal rule,” http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078923.pdf.
  110. E. A. Fritz, J. B. Geisbert, T. W. Geisbert, L. E. Hensley, and D. S. Reed, “Cellular immune response to marburg virus infection in cynomolgus macaques,” Viral Immunology, vol. 21, no. 3, pp. 355–363, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. S. M. Jones, H. Feldmann, U. Ströher et al., “Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses,” Nature Medicine, vol. 11, no. 7, pp. 786–790, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. C. C. Czerkinsky, L. A. Nilsson, and H. Nygren, “A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 109–121, 1983.
  113. M. Larsson, X. Jin, B. Ramratnam et al., “A recombinant vaccinia virus based ELISPOT assay detects high frequencies of pol-specific CD8 T cells in HIV-1-positive individuals,” AIDS, vol. 13, no. 7, pp. 767–777, 1999. View at Publisher · View at Google Scholar · View at Scopus
  114. J. R. Currier, E. G. Kuta, E. Turk et al., “A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays,” Journal of Immunological Methods, vol. 260, no. 1-2, pp. 157–172, 2002. View at Publisher · View at Google Scholar · View at Scopus
  115. M. P. Hernandez-Fuentes, A. N. Warrens, and R. I. Lechler, “Immunologic monitoring,” Immunological Reviews, vol. 196, pp. 247–264, 2003. View at Publisher · View at Google Scholar · View at Scopus
  116. P. Mooij, S. S. Balla-Jhagjhoorsingh, N. Beenhakker et al., “Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens,” Journal of Virology, vol. 83, no. 11, pp. 5881–5889, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. H. Streeck, N. Frahm, and B. D. Walker, “The role of IFN-γ Elispot assay in HIV vaccine research,” Nature Protocols, vol. 4, no. 4, pp. 461–469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. Y. Okamoto, T. Abe, T. Niwa, S. Mizuhashi, and M. Nishida, “Development of a dual color enzyme-linked immunospot assay for simultaneous detection of murine T helper type 1-and T helper type 2-cells,” Immunopharmacology, vol. 39, no. 2, pp. 107–116, 1998. View at Publisher · View at Google Scholar · View at Scopus
  119. K. L. Warfield, D. L. Swenson, D. L. Negley, A. L. Schmaljohn, M. J. Aman, and S. Bavari, “Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection,” Vaccine, vol. 22, no. 25-26, pp. 3495–3502, 2004. View at Publisher · View at Google Scholar · View at Scopus
  120. K. L. Warfield, D. L. Swenson, G. G. Olinger, W. V. Kalina, M. J. Aman, and S. Bavari, “Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge,” Journal of Infectious Diseases, vol. 196, supplement 2, pp. S430–S437, 2007. View at Publisher · View at Google Scholar
  121. R. A. Seder, P. A. Darrah, and M. Roederer, “T-cell quality in memory and protection: implications for vaccine design,” Nature Reviews Immunology, vol. 8, no. 4, pp. 247–258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. M. Roederer, J. M. Brenchley, M. R. Betts, and S. C. De Rosa, “Flow cytometric analysis of vaccine responses: how many colors are enough?” Clinical Immunology, vol. 110, no. 3, pp. 199–205, 2004. View at Publisher · View at Google Scholar · View at Scopus
  123. E. K. Leffel and D. S. Reed, “Marburg and Ebola viruses as aerosol threats,” Biosecurity and Bioterrorism, vol. 2, no. 3, pp. 186–191, 2004. View at Scopus
  124. K. L. Warfield, S. B. Bradfute, J. Wells et al., “Development and characterization of a mouse model for Marburg hemorrhagic fever,” Journal of Virology, vol. 83, no. 13, pp. 6404–6415, 2009. View at Publisher · View at Google Scholar · View at Scopus